Endoplasmic Reticulum Targeting to Amplify Immunogenic Cell Death for Cancer Immunotherapy

被引:306
|
作者
Deng, Hongzhang [1 ,2 ]
Zhou, Zijian [2 ]
Yang, Weijing [2 ]
Lin, Li-sen [2 ]
Wang, Sheng [2 ]
Niu, Gang [2 ]
Song, Jibin [1 ]
Chen, Xiaoyuan [2 ]
机构
[1] Fuzhou Univ, Coll Chem, MOE Key Lab Analyt Sci Food Safety & Biol, Fuzhou 350108, Fujian, Peoples R China
[2] NIBIB, Lab Mol Imaging & Nanomed LOMIN, NIH, Bethesda, MD 20892 USA
基金
中国国家自然科学基金; 美国国家卫生研究院;
关键词
Endoplasmic reticulum (ER) stress; Photodynamic therapy; Immunogenic cell death (ICD); abscopal effect; PHOTODYNAMIC THERAPY; NANOPARTICLES; NANOPLATFORM; COMBINATION; DELIVERY;
D O I
10.1021/acs.nanolett.9b05210
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Immunogenic cell death (ICD) elicited by photo-dynamic therapy (PDT) is mediated through generation of reactive oxygen species (ROS) that induce endoplasmic reticulum (ER) stress. However, the half-life of ROS is very short and the intracellular diffusion depth is limited, which impairs ER localization and thus limits ER stress induction. To solve the problem, we synthesized reduction-sensitive Ds-sP NPs (PEG-s-s-1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[amino-(polyethylene glycol)-2000] nanoparticles) loaded with an efficient ER-targeting photosensitizer TCPP-T ER (4,4',4 '',4'"-(porphyrin-5,10,15,20-tetrayOtetrakis(N-(24(4-methylphenyOsulfonamido)-ethyl)benzamide). The resulting Ds-sP/TCPP-T-ER NPs could selectively accumulate in the ER and locally generate ROS under near-infrared (NIR) laser irradiation, which induced ER stress, amplified ICD, and activated immune cells, leading to augmented immunotherapy effect. This study presents a novel ICD amplifying, ER-targeting PDT strategy that can effectively eradicate primary tumors under NIR exposure, as well as distant tumors through an abscopal effect.
引用
收藏
页码:1928 / 1933
页数:6
相关论文
共 50 条
  • [1] Emerging photodynamic nanotherapeutics for inducing immunogenic cell death and potentiating cancer immunotherapy
    Zhang, Shenwu
    Wang, Jing
    Kong, Zhiqiang
    Sun, Xinxin
    He, Zhonggui
    Sun, Bingjun
    Luo, Cong
    Sun, Jin
    BIOMATERIALS, 2022, 282
  • [2] Immunogenic cell death inducers for enhanced cancer immunotherapy
    Li, Yanhua
    Liu, Xiaohan
    Zhang, Xia
    Pan, Wei
    Li, Na
    Tang, Bo
    CHEMICAL COMMUNICATIONS, 2021, 57 (91) : 12087 - 12097
  • [3] Activation of pyroptosis by specific organelle-targeting photodynamic therapy to amplify immunogenic cell death for anti-tumor immunotherapy
    Zeng, Shuang
    Chen, Chen
    Zhang, Liuwei
    Liu, Xiaosheng
    Qian, Ming
    Cui, Hongyan
    Wang, Jingyun
    Chen, Qixian
    Peng, Xiaojun
    BIOACTIVE MATERIALS, 2023, 25 : 580 - 593
  • [4] Nanoparticle-mediated immunogenic cell death for cancer immunotherapy
    Qi, Haolong
    Li, Yuan
    Geng, Yingjie
    Wan, Xinhuan
    Cai, Xiaoqing
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 656
  • [5] Biomimetic Active Materials Guided Immunogenic Cell Death for Enhanced Cancer Immunotherapy
    Huang, Guojun
    Liu, Lanlan
    Pan, Hong
    Cai, Lintao
    SMALL METHODS, 2023, 7 (05)
  • [6] Applying nanotechnology to boost cancer immunotherapy by promoting immunogenic cell death
    Fu, Lvqin
    Ma, Xianbin
    Liu, Yuantong
    Xu, Zhigang
    Sun, Zhijun
    CHINESE CHEMICAL LETTERS, 2022, 33 (04) : 1718 - 1728
  • [7] A new paradigm for cancer immunotherapy: targeting immunogenic cell death-related noncoding RNA
    Sun, Guojuan
    He, Ling
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [8] Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy
    Gao, Jing
    Wang, Wei-qi
    Pei, Qing
    Lord, Megan S.
    Yu, Hai-jun
    ACTA PHARMACOLOGICA SINICA, 2020, 41 (07) : 986 - 994
  • [9] Current status of nanoparticle-mediated immunogenic cell death in cancer immunotherapy
    Tran, Tuan Hiep
    Tran, Thi Thu Phuong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 142
  • [10] Immunogenic cell death: A new strategy to enhancing cancer immunotherapy
    Dou, Lei
    Fang, Yu
    Yang, Huiyuan
    Ai, Guo
    Shen, Na
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01) : 2437918